RTX | N | IS | N | p Value | |
---|---|---|---|---|---|
Disease duration years, mean±SD | 9.1±7.1 | 101 | 4.1±6.6 | 72 | <0.0001 |
Organ manifestation | (%) | 103 | (%) | 72 | |
Renal (LN) | 58 | 53 | NS | ||
Musculoskeletal | 11 | 22 | 0.038 | ||
Haematological | 15 | 11 | NS | ||
Skin | 6 | 6 | NS | ||
CNS | 7 | 3 | NS | ||
Other | 3 | 5 | NS | ||
Reason for treatment | (%) | 103 | (%) | 72 | |
Controlling disease | 77 | 44 | <0.0001 | ||
Steroid-sparing | 1 | 14 | <0.0001 | ||
Both | 22 | 42 | 0.006 | ||
Disease activity | |||||
SLEDAI, mean±SD | 12.2±7.1 | 102 | 9.4±7.0 | 72 | 0.010 |
SLICC-DI, mean±SD | 1.6±3.4 | 96 | 0.6±1.0 | 72 | 0.014 |
SLEDAI, LN vs non-LN* | 14.6±6.2 vs 9.0±6.9 | 59 43 | 12.5±7.6 vs 5.9±4.3 | 38 34 | <0.0001 (within groups treatments) |
*SLEDAI between groups, treatments: LN, NS; non-LN p=0.029.
CNS, central nervous system; IS, immunosuppressive; LN, lupus nephritis; NS, not significant; RTX, rituximab; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.